These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22651555)

  • 21. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of modeling and simulation in drug development and regulatory review.
    Huang SM; Abernethy DR; Wang Y; Zhao P; Zineh I
    J Pharm Sci; 2013 Sep; 102(9):2912-23. PubMed ID: 23712632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
    Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
    Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Network-based drugs and biomarkers.
    Erler JT; Linding R
    J Pathol; 2010 Jan; 220(2):290-6. PubMed ID: 19921715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organs-on-chips at the frontiers of drug discovery.
    Esch EW; Bahinski A; Huh D
    Nat Rev Drug Discov; 2015 Apr; 14(4):248-60. PubMed ID: 25792263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation.
    Salter H; Holland R
    J Intern Med; 2014 Sep; 276(3):215-28. PubMed ID: 24605903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-based approaches to in silico pharmacology.
    Vidal D; Garcia-Serna R; Mestres J
    Methods Mol Biol; 2011; 672():489-502. PubMed ID: 20838981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Have animal models of disease helped or hindered the drug discovery process?
    Hunter AJ
    Ann N Y Acad Sci; 2011 Dec; 1245():1-2. PubMed ID: 22211963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation model-based drug discovery and development: quantitative and systems pharmacology.
    Allerheiligen SR
    Clin Pharmacol Ther; 2010 Jul; 88(1):135-7. PubMed ID: 20531467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The need for precompetitive integrative bionetwork disease model building.
    Friend SH
    Clin Pharmacol Ther; 2010 May; 87(5):536-9. PubMed ID: 20407459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proof of concept: a PhRMA position paper with recommendations for best practice.
    Cartwright ME; Cohen S; Fleishaker JC; Madani S; McLeod JF; Musser B; Williams SA
    Clin Pharmacol Ther; 2010 Mar; 87(3):278-85. PubMed ID: 20130568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
    Severino ME; Dubose RF; Patterson SD
    IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.
    Leong R; Vieira ML; Zhao P; Mulugeta Y; Lee CS; Huang SM; Burckart GJ
    Clin Pharmacol Ther; 2012 May; 91(5):926-31. PubMed ID: 22472993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario.
    Barbanoj MJ; Valle M; Kulisevsky J; Pérez V; Gambús P
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():139-44. PubMed ID: 12575481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in measuring single-cell pharmacology in vivo.
    Vinegoni C; Dubach JM; Thurber GM; Miller MA; Mazitschek R; Weissleder R
    Drug Discov Today; 2015 Sep; 20(9):1087-92. PubMed ID: 26024776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of DBS within drug discovery: development of a serial microsampling pharmacokinetic study in mice.
    Clark GT; Haynes JJ; Bayliss MA; Burrows L
    Bioanalysis; 2010 Aug; 2(8):1477-88. PubMed ID: 21083348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.
    LLerena A; Peñas-Lledó EM
    Drug Metab Pers Ther; 2015 Sep; 30(3):143-5. PubMed ID: 26353178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.